Biogen logo

Biogen Share Price Today

(NASDAQ: BIIB)

Biogen share price is $140.64 & ₹12,197.14 as on 22 Feb 2025, 2.30 'hrs' IST

$140.64

3.56

(2.6%)

Market is closed - opens 8 PM, 24 Feb 2025

View live Biogen share price in Dollar and Rupees. Guide to invest in Biogen stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Biogen, along with analyst recommendations, forecasts, and comprehensive financials.

Biogen share price movements

  • Today's Low: $137.88
    Today's High: $141.45

    Day's Volatility :2.52%

  • 52 Weeks Low: $128.51
    52 Weeks High: $238.00

    52 Weeks Volatility :46.0%

Biogen (BIIB) Returns

PeriodBiogen Inc.Sector (Health Care)Index (NASDAQ Composite)
3 Months
-11.39%
1.6%
2.7%
6 Months
-31.35%
-5.4%
10.8%
1 Year
-37.02%
-0.5%
21.7%
3 Years
-32.73%
15.1%
45.9%

Biogen (BIIB) Key Statistics

in dollars & INR

Previous Close
$137.08
Open
$138.0
Today's High
$141.445
Today's Low
$137.8763
Market Capitalization
$20.6B
Today's Volume
$1.8M
52 Week High
$238.0
52 Week Low
$128.511
Revenue TTM
$9.7B
EBITDA
$3.0B
Earnings Per Share (EPS)
$11.19
PE Ratio
12.57
Profit Margin
16.87%
Quarterly Earnings Growth YOY
0.06%
Return On Equity TTM
10.36%

How to invest in Biogen Stock (BIIB) from India?

It is very easy for Indian residents to invest directly in Biogen from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Biogen stock in both Indian Rupees (INR) and US Dollars (USD). Search for Biogen or BIIB on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Biogen or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Biogen shares which would translate to 0.006 fractional shares of Biogen as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Biogen, in just a few clicks!

Returns in Biogen (BIIB) for Indian investors in Rupees

The Biogen stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Biogen investment value today

Current value as on today

₹67,626

Returns

₹32,374

(-32.37%)

Returns from Biogen Stock

₹37,023 (-37.02%)

Dollar Returns

₹4,649 (+4.65%)

Indian investors sentiment towards Biogen (BIIB)

3.17%

Period: Jan 22, 2025 to Feb 21, 2025. Change in 30 Days versus previous period

Investment in Biogen Shares from India has grown by 3.17% over the past 30 days, indicating increased transactional activity.

23%

Period: Jan 22, 2025 to Feb 21, 2025. Change in 30 Days versus previous period

Search interest for Biogen Stock from India on INDmoney has increased by 23% in the last 30 days, reflecting an upward trend in search activity.

Indian Mutual Funds that invest in Biogen Stock (BIIB Ticker)

Global Institutional Holdings in Biogen

  • Vanguard Group Inc

    11.49%

  • PRIMECAP Management Company

    11.01%

  • BlackRock Inc

    10.53%

  • JPMorgan Chase & Co

    7.11%

  • State Street Corp

    5.04%

  • Wellington Management Company LLP

    3.38%

Analyst Recommendation on Biogen

Buy

    71%Buy

    28%Hold

    0%Sell

Based on 42 Wall street analysts offering stock ratings for Biogen(by analysts ranked 0 to 5 stars)

Based on 42 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
30
30
32
Hold
12
12
10
Sell
0
0
0

Analyst Forecast on Biogen Stock (BIIB)

What analysts predicted

Upside of 43.19%

Target:

$201.38

Current:

$140.64

Insights on Biogen Stock (Ticker Symbol: BIIB)

  • Price Movement

    In the last 7 days, BIIB stock has moved up by 2.4%
  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 2.46B → 2.45B (in $), with an average decrease of 0.5% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 583.6M → 266.8M (in $), with an average decrease of 32.4% per quarter
  • BIIB vs ABBV (1 yr)

    In the last 1 year, Abbvie Inc has given 14.3% return, outperforming this stock by 51.1%
  • BIIB vs LLY (3 yr)

    In the last 3 years, Eli Lilly And Company has given 38.8% return, outperforming this stock by 71.8%
  • Price to Sales

    ForBIIB every $1 of sales, investors are willing to pay $2.1, whereas for Abbvie Inc, the investors are paying $6.3 for every $1 of sales.

Biogen Technicals Summary

Sell

Neutral

Buy

Biogen is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Biogen (BIIB) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Biogen Inc. logo
-2.11%
-31.35%
-37.02%
-32.73%
-56.86%
Eli Lilly And Company logo
13.97%
-8.08%
13.53%
266.61%
532.41%
Johnson & Johnson logo
10.68%
-1.4%
0.28%
0.67%
11.23%
Merck & Co. Inc. logo
-7.38%
-23.02%
-30.86%
18.01%
10.05%
Novo Nordisk A/s logo
8.61%
-34.9%
-28.65%
80.34%
187.47%
Abbvie Inc logo
18.4%
2.35%
13.47%
37.69%
116.96%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Biogen Inc. logo
12.57
12.57
6.24
15.72
0.1
0.05
NA
114.65
Eli Lilly And Company logo
74.67
74.67
0.88
23.1
0.84
0.15
0.01
15.81
Johnson & Johnson logo
27.58
27.58
1.0
10.57
0.2
0.08
0.03
29.7
Merck & Co. Inc. logo
13.01
13.01
0.07
8.99
0.42
0.11
0.04
17.58
Novo Nordisk A/s logo
26.33
26.33
1.2
0.0
0.81
0.22
0.02
32.31
Abbvie Inc logo
84.05
84.05
2.64
12.26
0.62
0.08
0.03
1.88
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Biogen Inc. logo
Buy
$20.6B
-56.86%
12.57
16.87%
Eli Lilly And Company logo
Buy
$784.7B
532.41%
74.67
23.51%
Johnson & Johnson logo
Buy
$384.4B
11.23%
27.58
15.84%
Merck & Co. Inc. logo
Buy
$221.8B
10.05%
13.01
26.67%
Novo Nordisk A/s logo
Buy
$367.7B
187.47%
26.33
34.78%
Abbvie Inc logo
Buy
$354.6B
116.96%
84.05
7.59%

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of amyotrophic lateral sclerosis; FUMADERM for the treatment of plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Organization
Biogen
Employees
7605
CEO
Mr. Christopher A. Viehbacher
Industry
Health Technology

Management People of Biogen

NameTitle
Mr. Christopher A. Viehbacher
President, CEO & Director
Mr. Michael R. McDonnell CPA
Executive VP & CFO
Ms. Nicole Murphy
Executive VP and Head of Pharmaceutical Operations & Technology
Ms. Susan H. Alexander Esq.
Executive VP & Chief Legal Officer
Mr. Rachid Izzar
Executive VP and Head of Global Product Strategy & Commercialization
Ms. Robin C. Kramer
Senior VP & Chief Accounting Officer
Mr. Tim Power M.B.A., Ph.D.
Head of Investor Relations
Ms. Natacha Gassenbach
Chief Communication Officer & Head of Corporate Affairs
Mr. Adam Keeney Ph.D.
Executive VP & Head of Corporate Development
Dr. Ginger Gregory Ph.D.
Executive VP & Chief Human Resources Officer

Important FAQs about investing in BIIB Stock from India :

What is Biogen share price today?

Biogen share price today stands at $140.64, Open: $138.00 ; Previous Close: $137.08 ; High: $141.45 ; Low: $137.88 ; 52 Week High: $238.00 ; 52 Week Low: $128.51.

The stock opens at $138.00, after a previous close of $137.08. The stock reached a daily high of $141.45 and a low of $137.88, with a 52-week high of $238.00 and a 52-week low of $128.51.

Can Indians buy Biogen shares?

Yes, Indians can invest in the Biogen (BIIB) from India.

With INDmoney, you can buy Biogen at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Biogen at zero transaction cost.

How can I buy Biogen shares from India?

It is very easy to buy Biogen from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Biogen (BIIB) be purchased?

Yes, you can buy fractional shares of Biogen with INDmoney app.

What are the documents required to start investing in Biogen stocks?

To start investing in Biogen, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Biogen Stock (BIIB)?

Today’s highest price of Biogen (BIIB) is $141.45.

Today’s lowest price of Biogen (BIIB) is $137.88.

What is today's market capitalisation of Biogen?

Today's market capitalisation of Biogen BIIB is 20.6B

What is the 52 Week High and Low Range of Biogen Stock (BIIB)?

  • 52 Week High

    $238.00

  • 52 Week Low

    $128.51

What are the historical returns of Biogen (BIIB)?

  • 1 Month Returns

    -2.11%

  • 3 Months Returns

    -31.35%

  • 1 Year Returns

    -37.02%

  • 5 Years Returns

    -56.86%

Who is the Chief Executive Officer (CEO) of Biogen ?

Mr. Christopher A. Viehbacher is the current Chief Executive Officer (CEO) of Biogen.